MedTrace Logo

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

NCT00233675 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-04-12

No results posted yet for this study

Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Conditions

  • General Anxiety Disorder

Interventions

DRUG

GABITRIL (tiagabine hydrochloride; CEP-6671)

Sponsors & Collaborators

  • Cephalon

    lead INDUSTRY

Principal Investigators

  • Charles Brown, MD · Cephalon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233675 on ClinicalTrials.gov